ASCLF - Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines

• The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic.
• CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian vaccine, Sputnik V.
• Sinovac has conducted large-scale trials in Brazil and other countries, though the efficacy rates varied from 50% to 91%. The low number was from Brazil and may reflect the difficulty of fighting Brazil's variant of the SARS-CoV-2 infection.

For further details see: